Brand Name

Ampyra

Generic Name
Dalfampridine
View Brand Information
FDA approval date: March 01, 2010
Classification: Potassium Channel Blocker
Form: Tablet

What is Ampyra (Dalfampridine)?

AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis . This was demonstrated by an increase in walking speed. AMPYRA ® is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis . This was demonstrated by an increase in walking speed .

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Randomised, Double-Blind, Placebo-Controlled, Crossover Study Investigating the Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users

Summary: The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.

Dalfampridine Combined With Physical Therapy for Mobility Impairment in People With Multiple Sclerosis

Summary: The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent da...

Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury

Summary: The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.